Estimation Methods for Estimands Using the Treatment Policy Strategy; a Simulation Study Based on the PIONEER 1 Trial
Pharmaceutical Statistics · 2025
DOI: 10.1002/pst.2472 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceutical Statistics, 2025. Verfasst von James Bell und 8 weiteren Autor:innen. Beteiligte Einrichtung: Biostatistics and Clinical Data Sciences, Elderbrook Solutions GmbH, Buckinghamshire, UK. Hauptthemen laut MEDLINE: Computer Simulation, Clinical Trials, Phase III as Topic, Models, Statistical. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 34 Literaturangaben.
Abstract (Originalsprache)
Estimands using the treatment policy strategy for addressing intercurrent events are common in Phase III clinical trials. One estimation approach for this strategy is retrieved dropout whereby observed data following an intercurrent event are used to multiply impute missing data. However, such methods have had issues with variance inflation and model fitting due to data sparsity. This paper introduces likelihood‐based versions of these approaches, investigating and comparing their statistical properties to the existing retrieved dropout approaches, simpler analysis models and reference‐based multiple imputation. We use a simulation based upon the data from the PIONEER 1 Phase III clinical trial in Type II diabetics to present complex and relevant estimation challenges. The likelihood‐based methods display similar statistical properties to their multiple imputation equivalents, but all retrieved dropout approaches suffer from high variance. Retrieved dropout approaches appear less biased than reference‐based approaches, resulting in a bias‐variance trade‐off, but we conclude that the large degree of variance inflation is often more problematic than the bias. Therefore, only the simpler retrieved dropout models appear appropriate as a primary analysis in a clinical trial, and only where it is believed most data following intercurrent events will be observed. The jump‐to‐reference approach may represent a more promising estimation approach for symptomatic treatments due to its relatively high power and ability to fit in the presence of much missing data, despite its strong assumptions and tendency toward conservative bias. More research is needed to further develop how to estimate the treatment effect for a treatment policy strategy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Biostatistics and Clinical Data Sciences, Elderbrook Solutions GmbH, Buckinghamshire, UK.
- Statistics & Data Science Innovation Hub, GlaxoSmithKline, London, UK.
- Advanced Quantitative Sciences, Novartis Pharma AG, Basel, Switzerland.
- Methods and Outreach, Biostatistics, Novo Nordisk A/S, Soeborg, Denmark & Dept. of Public Health, University of Southern Denmark, Odense, Denmark.
- Human Medicines, European Medicines Agency, Domenico Scarlattilaan 6, Amsterdam, The Netherlands.
- Biostatistics, Quantitative Sciences & Development Operations, Biogen International GmbH, Baar, Zug, Switzerland.
ORCID-Profile: James Bell, Thomas Drury, Tobias Mütze, Christian Bressen Pipper, Lorenzo Guizzaro, Marian Mitroiu, Khadija Rerhou Rantell, Marcel Wolbers, David Wright
Zitieren
APA
Bell, J., Drury, T., Mütze, T., Pipper, C. B., Guizzaro, L., Mitroiu, M., Rantell, K. R., Wolbers, M., & Wright, D. (2025). Estimation Methods for Estimands Using the Treatment Policy Strategy; a Simulation Study Based on the PIONEER 1 Trial. Pharmaceutical Statistics. https://doi.org/10.1002/pst.2472
Vancouver
Bell J, Drury T, Mütze T, Pipper CB, Guizzaro L, Mitroiu M, et al. Estimation Methods for Estimands Using the Treatment Policy Strategy; a Simulation Study Based on the PIONEER 1 Trial. Pharmaceutical Statistics. 2025. doi:10.1002/pst.2472
BibTeX
@article{Bell2025,
author = {Bell, James and Drury, Thomas and Mütze, Tobias and Pipper, Christian Bressen and Guizzaro, Lorenzo and Mitroiu, Marian and Rantell, Khadija Rerhou and Wolbers, Marcel and Wright, David},
title = {Estimation Methods for Estimands Using the Treatment Policy Strategy; a Simulation Study Based on the PIONEER 1 Trial},
journal = {Pharmaceutical Statistics},
year = {2025},
doi = {10.1002/pst.2472}
}
EUVIMED